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Irritable bowel syndrome (IBS), a disorder of the brain-gut axis, is characterised by the
absence of reliable biological markers.Tryptophan is an essential amino acid that serves as
a precursor to serotonin but which can alternatively be metabolised along the kynurenine
pathway leading to the production of other neuroactive agents. We previously reported
an increased degradation of tryptophan along this immunoresponsive pathway in IBS.
Recently, altered cytokine production following activation of speciﬁc members of the
toll-like receptor (TLR) family (TLR1-9) has also been demonstrated in IBS. However, the
relationship betweenTLR activation and kynurenine pathway activity in IBS is unknown. In
this study, we investigated whether activation of speciﬁcTLRs elicits exaggerated kynure-
nine production in IBS patients compared to controls. Whole blood from IBS patients and
healthy controls was cultured with a panel of nine different TLR agonists for 24 h. Cell
culture supernatants were then analyzed for both tryptophan and kynurenine concentra-
tions, as were plasma samples from both cohorts. IBS subjects had an elevated plasma
kynurenine:tryptophan ratio compared to healthy controls. Furthermore, we demonstrated
a differential downstream proﬁle of kynurenine production subsequent toTLR activation in
IBS patients compared to healthy controls.This proﬁle included alterations atTLR1/2,TLR2,
TLR3, TLR5, TLR7, and TLR8. Our data expands on our previous understanding of altered
tryptophan metabolism in IBS and suggests that measurement of tryptophan metabolites
downstream of TLR activation may ultimately ﬁnd utility as components of a biomarker
panel to aid gastroenterologists in the diagnosis of IBS. Furthermore, these studies impli-
cate the modulation of TLRs as means through which aberrant tryptophan metabolism
along the kynurenine pathway can be controlled, a novel potential therapeutic strategy in
this and other disorders.
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INTRODUCTION
The diagnosis of irritable bowel syndrome (IBS), a highly preva-
lent functional gastrointestinal disorder (FGID), is currentlymade
based on the presence of a characteristic symptomproﬁle (abdom-
inal pain/discomfort,bloating/distension,alterations in defecatory
function) in the absence of a demonstrable organic disease of
the gastrointestinal tract (GIT; Drossman and Dumitrascu, 2006).
This diagnostic scheme reﬂects the lack of reproducible biological
markers of this heterogeneous disorder, a serious impediment to
advancing our understanding of its pathophysiology (Clarke et al.,
2009b). The concept of IBS as a disorder of the brain-gut axis is
nowgenerally accepted and this has facilitated someprogress in the
area (Ohman and Simren, 2007, 2010). Recently, indices of a low
grade immune activation have been reported in IBS, including ele-
vations in circulating cytokines (Dinan et al., 2006; Liebregts et al.,
2007; Dinan et al., 2008; Scully et al., 2010) and pro-inﬂammatory
polyunsaturated fatty acids (Clarke et al., 2010) as well as evidence
of enhanced immune cell activation, both systemically (Ohman
et al., 2009a,b) and locally within the GIT (Cremon et al., 2009).
A growing appreciation of the potential impact of this increased
inﬂammatory state on the brain-gut axis (Quigley, 2006; Dantzer
et al., 2008; O’Malley et al., 2011) as well as an improved under-
standing of the inﬂuence of the GIT on mood and cognition
(Forsythe et al., 2010; Grenham et al., 2011; Mayer, 2011; Bercik
et al., 2012; Kennedy et al., 2012), has led to an exploration
of a potential role for tryptophan and its associated metabolic
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pathways in IBS. Tryptophan is an essential amino acid that serves
as a precursor to serotonin (5-HT), a key neurotransmitter within
both the enteric nervous system (ENS) and central nervous system
(CNS; Ruddick et al., 2006; Forsythe et al., 2010). An alternative
and physiologically dominant fate for tryptophan is degrada-
tion along the kynurenine pathway leading to the production of
neuroprotective compounds like kynurenic acid and neurotoxic
compounds like quinolinic acid (Schwarcz and Pellicciari, 2002).
Dysregulation of tryptophan metabolism is thus poised to impact
onmood and cognition within the CNS as well as secretion,motil-
ity, and perception in the ENS (Crowell, 2004; Forsythe et al.,
2010). Crucially, indoleamine-2.3-dioxygenase (IDO), one of two
key primary kynurenine pathway enzymes, is immunoresponsive
and studies, to date, have indicated an increase in IDO activity in
both male and female subjects with IBS (Fitzgerald et al., 2008;
Clarke et al., 2009a).
Mechanistic insights into the inﬂammationobserved in IBS and
the associated downstream consequences are currently lacking.
Toll-like receptors (TLRs) are pattern recognition receptors inte-
gral to the functioning of the innate immune system and respond
to a variety of bacterial and viral cell components, resulting in
increased production of inﬂammatory cytokines (Takeuchi and
Akira, 2010). Recent evidence from both relevant animal models
and biopsies from IBS sufferers have demonstrated altered expres-
sion of certain TLRs in the colonicmucosa (McKernan et al., 2009;
Brint et al., 2011). Increased TLR2 expression on bloodmonocytes
in IBS patients has also been reported (Ohman et al., 2012). More-
over it has recently been demonstrated that IBS patients have a
distinct patternof peripheral TLRactivity as indicatedbymeasure-
ments of cytokine production following whole blood stimulation
(McKernan et al., 2011). Although it is known that TLR activa-
tion can lead to alterations in IDO expression (Mahanonda et al.,
2007), the potential consequences for tryptophan metabolism in
IBS remain unknown.
In this study we investigated the potential functional conse-
quences of TLR activation on brain-gut axis signaling in terms of
perturbations in tryptophan metabolism. This was based on the
hypothesis that IBS patients would exhibit a downstream pattern
of tryptophan degradation along the kynurenine pathway subse-
quent to activation of TLRs with their speciﬁc ligands that was
distinct from healthy control subjects.
MATERIALS AND METHODS
STUDY POPULATION
The study protocol was approved by the University College Cork
(UCC) Clinical Research Ethics Committee. IBS patients were
recruited from a university IBS database comprised of individuals
who had either attended gastroenterology clinics at Cork Univer-
sity Hospital (CUH) or had responded to direct advertisement on
the university campus or a local newspaper regarding participa-
tion in IBS research. Thirty seven healthy controls were recruited
from staff at both UCC and CUH. Twenty ﬁve individuals aged
between 18 and 65 years who satisﬁed Rome II criteria for IBS and
inwhomorganic gastrointestinal diseases and clinically signiﬁcant
systemic diseases had been excluded,were considered for inclusion
in the study. Subjects who had undergone any abdominal surgery,
with the exception of hernia repair and appendectomy, were also
excluded. No postinfectious IBS (PI-IBS) subjects were included
in the recruitment and IBS patients were not selected on the basis
of predominant bowel habit, although this was recorded according
to the Rome II classiﬁcations. All subjects completed a question-
naire to assess both IBS severity (Francis et al., 1997) and current
mood (Spitzer et al., 1999).
BIOLOGICAL ASSAYS
Fifteen milliliters of whole blood was collected between 11:00 and
13:00 hours from each healthy control and IBS patient. Collected
whole blood (15mL) was added to an equal volume of Histopaque
1077 (Sigma, St Louis, MO, USA) in a sterile 50mL tube and cen-
trifuged at 400× g for 30min at room temperature. Plasma on the
upper layer was transferred to a separate tube and stored at −80˚C
for future analysis. Collected whole blood (2mL) was diluted 1:10
in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM; Gibco, Dublin,
Ireland). Blood was aliquoted into 24 well plates and cultured in a
37˚C incubator with 5% CO2. Each blood sample was cultured in
duplicate in DMEM cell culture medium supplemented with 10%
Fetal Calf Serum (Sigma,Dublin, Ireland) with or without the fol-
lowing TLR ligands from a Human TLR agonist kit (Invivogen,
San Diego, CA, USA) for 24 h:
TLR1/2-Palmitoyl-3-cysteine-serine-lysine 4 (Pam3Cys);TLR2-
heat-killedListeriamonocytogenes (HKLM);TLR3-Polyriboinosinic
polyribocytidylic acid (Poly I:C); TLR4-Lipopolysaccharide (LPS);
TLR5-Salmonella typhimurium Flagellin; TLR6/2-FSL-1; TLR7-
Imiquimod; TLR8-ssRNA40; TLR9-ODN2006. Agonists were
reconstituted in endotoxin free water (supplied in kit) to a ﬁnal
concentration of 1μgmL−1 except for HKLM (108 cells) and
Poly I:C (10μgmL−1). Subsequently, supernatants from both
untreated and stimulated cells were aspirated and stored at −80˚C
for future analysis.
HPLC ASSAY FOR TRYPTOPHAN AND KYNURENINE
Tryptophan and kynurenine were determined by high perfor-
mance liquid chromatography (HPLC): this involved using a sys-
tem comprising a Waters 510 pump (Waters Ireland, Dublin, Ire-
land), 717plus cooled autosampler, a 996 PDA detector, a Hewlett
Packard 1046A Fluorescent Detector (Waters Ireland, Dublin,
Ireland), a waters bus SAT/IN module and a croco-cil column
oven. System components were used in conjunction with Waters
Empower software (Waters Ireland, Dublin, Ireland). All samples
were injected onto a reversed phase Luna 3μC18(2) 150× 2mm
column (Phenomenex, Macclesﬁeld, UK), which was protected
by Krudkatcher disposable precolumn ﬁlters and security guard
cartridges (Phenomenex). HPLC grade acetonitrile, acetic acid,
and perchloric acid were obtained from Fisher Scientiﬁc Ireland
(Dublin, Ireland). The analysis method was based on that by
Herve et al. (1996). The mobile phase consisted of 50mmol L−1
acetic acid, 100mmol L−1 Zinc Acetate with 3% (v/v) acetoni-
trile and was ﬁltered through a 0.45 μm Millipore ﬁlter (AGB,
Dublin, Ireland) and vacuum degassed prior to use. Separations
were achieved by isocratic elution at 0.3mLmin−1. The ﬂuo-
rescent detector was set to an excitation wavelength of 254 nm
and an emission wavelength of 404 nm. The PDA detector start
wavelength was 210 nm and the end wavelength was 400 nm with
chromatogram extraction at 330 nm. Working standard dilutions
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were prepared from millimolar stock solutions of each standard
and stored at −80˚C until required for analysis. Samples were
deproteinized by the addition of 20μL of 4mol L−1 perchloric
acid to 200μL of plasma spiked with 3-nitro-l-tyrosine as inter-
nal standard. Twenty microliters of either sample or standard
was injected onto the HPLC system and chromatograms gener-
ated were processed using Waters Empower software. Analytes
were identiﬁed based on their characteristic retention time and
their concentrations determined using Analyte:Internal standard
peak height ratios; these were measured and compared with stan-
dard injections which were run at regular intervals during the
sample analysis. Results were expressed at ng analyte per mL of
supernatant/plasma.
STATISTICS
The sample size was determined by a power calculation based
on our previous data and aimed at detecting differences between
IBS patients and controls at the 0.05 level. Data was expressed as
mean± SEM. Statistical analysis was carried out using SPSS 18
for Windows (SPSS, Inc., Chicago, IL, US). Plasma tryptophan,
kynurenine, and the kynurenine:tryptophan ratio were compared
using an unpaired two-tailed Student’s t -test and differences con-
sidered signiﬁcant at the p< 0.05 level. Bonferroni corrections
for multiple comparisons were applied as required. TLR agonist
induced alterations in,kynurenine and the kynurenine:tryptophan
ratio were determined using a two-wayANOVA and by Bonferroni
post hoc tests.
RESULTS
BASELINE CHARACTERISTICS
There were no signiﬁcant differences between IBS patients (5M,
20F) and controls (13M, 25F) in terms of age (41.32± 2.234 vs.
36.63± 1.821, p = 0.11) or bodymass index (BMI; 24.88± 0.7089
vs. 23.96± 0.8668, p = 0.45). According to Rome II sub clas-
siﬁcation of predominant bowel habit, nine had constipation-
predominant IBS (IBS-C), eight had diarrhea-predominant IBS
(IBS-D), and eight had alternating IBS (IBS-A). There were three
current smokers in each group. Eleven IBS subjects (44%) met
criteria for a current psychiatric co-morbidity. According to IBS
symptom severity scores, 5 patients rated their symptoms as mild,
12 as moderate and 8 as severe.
PLASMA TRYPTOPHAN AND KYNURENINE CONCENTRATIONS
There was no signiﬁcant difference in plasma tryptophan
levels between controls and IBS groups (10.0± 0.4 vs.
10.5± 0.7μgmL−1, p = 0.51). Plasma kynurenine levels were sig-
niﬁcantly elevated in comparison to controls levels in IBS patients
(0.39± 0.02 vs. 0.50± 0.05μgmL−1, p< 0.05) as was the kynure-
nine:tryptophan ratio (0.03991± 0.00222 vs. 0.04795± 0.00315,
p< 0.05), an index of IDO activity (Figures 1A–C).
TLR AGONIST INDUCED ALTERNATIONS IN TRYPTOPHAN
DEGRADATION.
Concentrations of tryptophan and kynurenine following TLR
stimulation are given in Tables 1 and 2 respectively.
Two-way ANOVA analysis revealed a signiﬁcant interaction
between disease state and treatment (F3,126 = 5.867, p< 0.05) for
the kynurenine:tryptophan ratio following stimulation of whole
blood with the TLR1/2 agonist Pam3Csk. Post hoc analysis indi-
cated a signiﬁcant reduction in this ratio, in the IBS group, in
stimulated preparations compared to the unstimulated samples
(0.01774± 0.00089 vs. 0.01493± 0.00098,p< 0.05) with no alter-
ation in this ratio in the samples taken from the healthy controls
(Figure 2A). Two-way ANOVA analysis revealed a signiﬁcant
interaction between disease state and treatment (F3,126 = 8.475,
p< 0.01) following stimulation of whole blood with the TLR2
agonist HKLM. Post hoc analysis revealed a signiﬁcant increase in
this ratio in the healthy control group in stimulated vs. unstimu-
lated samples (0.01681± 0.0006 vs. 0.02159± 0.00098, p< 0.001)
with no alteration in this ratio in the samples taken from IBS
patients (Figure 2B). There was a trend toward a signiﬁcant
interaction between disease state and treatment (F3,126 = 2.887,
p = 0.092) following stimulation with the TLR3 agonist Poly I:C.
Post hoc analysis indicated a signiﬁcant increase in the ratio in
the healthy control group in stimulated vs. unstimulated samples
(0.01681± 0.0006 vs. 0.01907± 0.00092, p< 0.05) with no alter-
ation in the ratio being demonstrated in the samples taken from
IBS patients (Figure 2C).
There was no signiﬁcant interaction between disease state
and treatment following stimulation with the TLR4 ago-
nist LPS (F3,125 = 0.157, p = 0.962). Post hoc analysis indi-
cated a signiﬁcant increase in the ratio in the stimu-
lated compared to unstimulated samples from both controls
(0.01681± 0.0006 vs. 0.02354± 0.00112, p< 0.001) and IBS
patients (0.01774± 0.00089 vs. 0.02367± 0.00137, p< 0.001;
Figure 3A). There was a trend toward a signiﬁcant interac-
tion between disease state and treatment following stimula-
tion with the TLR5 agonist ﬂagellin (F3,124 = 3.604, p = 0.06).
The kynurenine:tryptophan ratio was signiﬁcantly elevated
from unstimulated levels only in the samples taken from
IBS patients (0.01774± 0.00089 vs. 0.02259± 0.0015, p< 0.01;
Figure 3B).
There was no signiﬁcant interaction between disease state and
treatment following stimulation with the TL6/2 agonist FSL1
(F1,124 = 1.026, p = 0.313) not was there any alteration in the
kynurenine:tryptophan ratio in either healthy controls or IBS
subjects (Figure 3C).
There was no signiﬁcant interaction between disease state
and treatment following stimulation with the TLR7 agonist
imiquimod (F3,125 = 0.146, p = 0.703) although this agonist
did induce an increase in the kynurenine:tryptophan ratio in
stimulated samples from control subjects (0.01681± 0.0006 vs.
0.01954± 0.00087, p< 0.05) that was not evident in their IBS
counterparts (Figure 4A). There was a trend toward a signif-
icant interaction between disease state and treatment follow-
ing stimulation of samples with the TLR8 agonist ssRNA40
(F3,124 = 3.491, p = 0.064). This TLR ligand induced an increase
in the kynurenine:tryptophan ratio only in the stimulated sam-
ples from IBS patients (0.01774± 0.00089 vs. 0.02166± 0.00161,
p< 0.05; Figure 4B). There was no signiﬁcant interaction between
disease state and treatment following stimulation with the TLR9
agonist ODN2006 (F3,125 = 2.324, p = 0.131) nor was there any
alteration in the kynurenine:tryptophan ratio in the stimulated
samples from either healthy control or IBS subjects (Figure 4C).
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FIGURE 1 | (A) Plasma tryptophan concentrations (μgmL−1) in healthy
controls and IBS patients. (B) Plasma kynurenine concentrations (μgmL−1) in
healthy controls and IBS patients. (C) Plasma kynurenine:tryptophan
(Kyn:Tryp) ratio in healthy controls and IBS patients. Data are expressed as
means±SEM. Statistical differences between healthy controls and IBS
patients were determined using Student’s t -test. *p<0.05.
Table 1 |Tryptophan concentrations (μgmL−1) in unstimulated and
TLR agonist stimulated whole blood supernatants from healthy
controls and IBS patients.
Control IBS
TLR stimulation Tryptophan p Tryptophan p
Unstimulated 13.5±0.2 N/A 13.7±0.3 N/A
1/2 (Pam3Cys) 11.7±0.2 *** 12.0±0.3 $$
2 (HKLM) 13.1±0.3 — 12.1±0.3 $$
3 (Poly I:C) 11.8±0.3 *** 12.3±0.2 $$
4 (LPS) 13.7±0.4 — 13.7±0.4 —
5 (Flagellin) 13.3±0.3 — 13.3±0.3 —
6/2 (FSL1) 12.6±0.2 * 13.2±0.3 —
7 (Imiquimod) 13.0±0.2 — 13.0±0.2 —
8 (ssRNA40) 12.6±0.3 * 12.9±0.2 —
9 (ODN2006) 13.4±0.5 — 13.0±0.5 —
Data are expressed as means±SEM. Statistical differences between stimu-
lated and unstimulated groups were determined using Bonferroni post hoc test.
*p<0.05, Healthy control unstimulated vs.TLR agonist stimulated; ***p<0.001,
healthy control unstimulated vs.TLR agonist Stimulated; $$ p<0.01, IBS unstim-
ulated vs. stimulated; — p>0.05.
DISCUSSION
Previous reports from our laboratory have indicated increased
degradation of tryptophan along the kynurenine pathway and
highlighted the potential utility of these indices as biological
Table 2 | Kynurenine concentrations (μgmL−1) in unstimulated and
TLR agonist stimulated whole blood supernatants from healthy
controls and IBS patients.
Control IBS
TLR stimulation Kynurenine p Kynurenine p
Unstimulated 0.22±0.01 N/A 0.24±0.01
1/2 (Pam3Cys) 0.21±0.01 — 0.18±0.01 $$$
2 (HKLM) 0.27±0.01 *** 0.20±0.01 $
3 (Poly I:C) 0.22±0.01 — 0.19±0.01 $$
4 (LPS) 0.33±0.01 *** 0.32±0.02 $$$
5 (Flagellin) 0.23±0.01 — 0.30±0.02 $$
6/2 (FSL1) 0.21±0.01 — 0.21±0.01 —
7 (Imiquimod) 0.25±0.01 — 0.26±0.02 —
8 (ssRNA40) 0.23±0.01 — 0.28±0.02 —
9 (ODN2006) 0.25±0.01 0.21±0.01 —
Data are expressed as means±SEM. Statistical differences between stimu-
lated and unstimulated groups were determined using Bonferroni post hoc test.
***p<0.001, Healthy control unstimulated vs.TLR agonist stimulated; $ p<0.05,
IBS unstimulated vs. TLR agonist stimulated; $$ p<0.01, IBS unstimulated
vs. stimulated; $$$ p<0.001 IBS unstimulated vs. TLR agonist stimulated; —
p>0.05.
markers of IBS (Fitzgerald et al., 2008; Clarke et al., 2009a). Here
we have conﬁrmed these ﬁndings by demonstrating increased
plasma kynurenine concentrations as well as an elevation in the
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FIGURE 2 | Kynurenine:tryptophan (Kyn:Tryp) ratio in unstimulated
whole blood supernatants from healthy controls and IBS patients and
following stimulation with: (A)TLR1/2 agonist Pam3Csk, (B)TLR2
agonist HKLM, and (C)TLR3 agonist Poly I:C. Data are expressed as
mean±SEM. Statistical differences between treatments and disease
states were determined using two-way ANOVA with Bonferroni post hoc
test. *p<0.05, Healthy control stimulated vs. unstimulated; ***p<0.001,
healthy control stimulated vs. unstimulated; $ p<0.05, IBS stimulated vs.
unstimulated.
kynurenine:tryptophan ratio in our IBS cohort compared to con-
trols. Moreover, we have demonstrated, for the ﬁrst time, that
IBS patients exhibit a distinct tryptophan degradation proﬁle
downstreamof TLR activation that is different from that of healthy
controls, as indicated by the kynurenine:tryptophan ratio in the
supernatants of whole blood preparations.
The pathophysiological relevance of increased activity along
the kynurenine pathway in the plasma of IBS patients remains to
be deﬁned as does the source of such alterations. Of the TLRs that
have previously been demonstrated to be upregulated in the colon
in IBS (Brint et al., 2011) and to have an elevated cytokine release
proﬁle (McKernan et al., 2011), both TLR5 and TLR8 induced, on
activation, an increase in the kynurenine:tryptophan ratio in our
experimental system. It has recently been shown that alterations
in gastrointestinal IDO activity in Crohns’s disease correlate with
systemic indices of kynurenine pathway activation (Gupta et al.,
FIGURE 3 | Kynurenine:tryptophan (Kyn:Tryp) ratio in unstimulated
whole blood supernatants from healthy controls and IBS patients and
following stimulation with: (A)TLR4 agonist LPS, (B)TLR5 agonist
flagellin, and (C)TLR6/1 agonist FSL1. Data are expressed as
mean±SEM. Statistical differences between treatments and disease
states were determined using two-way ANOVA with Bonferroni post hoc
test. ***p<0.001, Healthy control stimulated vs. unstimulated; $ p<0.05,
IBS stimulated vs. unstimulated; $$$ p<0.001, IBS stimulated vs.
unstimulated. There was no signiﬁcant interaction between disease state
and treatment following stimulation with theTL6/2 agonist FSL1
(F 1,124 =1.026, p =0.313) not was there any alteration in the
kynurenine:tryptophan ratio in either healthy controls or IBS subjects
(Figure 3C).
2011).Moreover, it is becoming increasingly apparent that periph-
eral blood alterations in kynurenine pathway metabolites can
manifest at the CNS level (Raison et al., 2009) and thatmodulation
of systemic pathway activity might be a useful therapeutic strat-
egy (Reinhart and Kelly, 2011; Zwilling et al., 2011). Nevertheless,
it will be important to determine whether the ﬁndings presented
here are indeed reﬂected at the level of the intestinal compartment,
an important site of tryptophanmetabolism and serotonergic sig-
naling in the periphery and further studies using supernatants
from mucosal biopsies will be of value in this regard.
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FIGURE 4 | Kynurenine:tryptophan (Kyn:Tryp) ratio in unstimulated
whole blood supernatants from healthy controls and IBS patients and
following stimulation with: (A)TLR 7 agonist Imiquimod, (B)TLR8
agonist ssRNA40, and (C)TLR9 agoinst ODN2006. Data are expressed as
mean±SEM. Statistical differences between treatments and disease
states were determined using two-way ANOVA with Bonferroni post hoc
test. *p<0.05, Healthy control stimulated vs. unstimulated; $ p<0.05, IBS
stimulated vs. unstimulated.
The differential tryptophan degradation proﬁle at TLR1/2,
TLR2, and TLR3 is an important ﬁnding. These receptors are
expressed at both intracellular and extracellular domains (Akira
and Takeda, 2004; Sioud, 2006) and our data suggests the presence,
in IBS, of TLR dysfunction at the level of both the cell membrane
and the endosome. It is also noteworthy that TLRs can interact
at a functional level to limit or inhibit the normal response to a
particular ligand (Hajjar et al., 2001), a feature which may be of
relevance to the reduced kynurenine:tryptophan ratio observed
in IBS patients following stimulation with the TLR1/2 ligand. An
alternative explanation, given that our ratio alterations following
stimulation of TLR1/2 and TLR3 are derived from reductions in
tryptophan concentrations in conjunction with decreased kynure-
nine, may involve the sequestering of tryptophan for the diverse
cellular processes in which it is involved. Certain cytokines, for
example, can upregulate tryptophan hydroxylase expression, the
rate-limiting enzyme in the conversion of tryptophan to serotonin
(Lisak et al., 2011). Future studies will also need to address whether
a differential leukocyte distribution might account for our ﬁnd-
ings although recent studies suggest that cellular activation might
be a more important factor (Ohman et al., 2009a,b).
In any case, the blunted kynurenine production at TLR2 and
TLR3 in our IBS cohort is perplexing given the enhanced produc-
tion of TNF-α and IL-8 demonstrated at those receptor subtypes,
respectively, in our earlier study (McKernan et al., 2011) and the
recently reported increased TLR2 expression on blood monocytes
in IBS patients (Ohman et al., 2012). It is, however, worth noting
that combinations of elevated cytokines may favour kynurenine
production over the singular increases described at these recep-
tor subtypes (Taylor and Feng, 1991) and that the availability of
certain co-factors is also required (Muller and Schwarz, 2007).
Additionally, the spontaneous release of IL-8 from unstimulated
samples, a previously reported phenomenon (Molina et al., 2006;
Horton and Remick, 2010), from both groups and the baseline dif-
ferences in the concentration of this cytokine may have obscured
the impact that post-stimulation alterations in IL-8 production
may have produced. Also of relevance is that repeated stimulation
of speciﬁc TLRs with their ligands can induce unresponsiveness or
immunotolerance, at least in cell line studies (Ehlers and Ravetch,
2007; Gomez-Llorente et al., 2010). This raises the possibility that
the defective response at TLR2 and TLR3 in IBS subjects might
alternatively be due to prolonged stimulation by endogenous lig-
ands. This is in line with suggestions that activation of TLRs by
their endogenous ligands might have a role in the promotion
of systemic inﬂammation (Marshak-Rothstein, 2006). Interest-
ingly host mRNA can activate TLR3 (Kariko et al., 2004) and
high mobility group box 1 (HMGB1) is a ligand for TLR2 (Yu
et al., 2006). Total plasma mRNA levels remain to be proﬁled in
IBS and although fecal HMGB1 has been proposed as a novel
marker of intestinal inﬂammation, it is also uncharacterised in the
disorder.
Interestingly, we found that the downstream consequences of
TLR4 activation for tryptophan metabolism are equivalent in
both healthy controls and IBS patients. Previously we reported
an increased release of the same two cytokines (IL-1B, TNF-α)
in IBS patients following stimulation of this receptor with LPS
as occurred following TLR5 activation with ﬂagellin (McKernan
et al., 2011). At ﬁrst glance, it appears unusual that an exagger-
ated release of the same two cytokines would elicit differential
responses in termsof kynurenine pathway indices at differentTLRs
if the immunoresponsive enzyme IDOmediates the effectswe have
observed. However, it should be noted that the magnitude of the
cytokine response following TLR4 stimulation is greater than that
induced following TLR5 activation suggesting that themoremod-
est cytokine release pattern at the latter receptor may be required
to tease apart the differential downstream effects of TLR stimu-
lation on kynurenine production. The cellular distribution of the
TLRs may also be of importance: it is worth noting that TLR4 is
much more highly expressed than TLR5 in monocytes (Hornung
et al., 2002) and LPS stimulation of whole blood primarily results
in cytokine release from this cell type (Pace and Heim, 2011). In
contrast, TLR5 is more highly expressed in NK cells and T cells
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than TLR4, although the magnitude of dominance TLR5 enjoys
in these cell populations does not match the superiority of TLR4
in terms of monocyte expression patterns. Although we did not
analyze the cellular composition of our whole blood preparations,
this theory is consistent with the observation that IBS subjects dis-
play an increased level of T-cell activation (Ohman et al., 2009a).
This explanation also reﬂects the view in the literature that IBS is
a disorder characterised by a low grade inﬂammation as opposed
to an immune disorder per se (Clarke et al., 2009b). However it
should also be noted that TLR4 stimulation increased kynurenine
concentrations without altering tryptophan concentrations which
may suggest the involvement of enzymatic components of the
kynurenine pathway other than IDO. Indeed differential activa-
tion of kynurenine pathway enzymes can be a feature of a systemic
immune challenge with LPS (Connor et al., 2008).
A limitation of the current study is that whole blood stimu-
lations of TLRs may only partially model the complexity of the
in vivo response. This is especially pertinent when one considers
that the entire family of receptors may be simultaneously sus-
ceptible to activation in vivo depending on the combination of
ligands present at physiologically relevant concentrations. Indeed,
it is known that combinations of TLR ligands can either syner-
gistically induce cytokine gene expression (Makela et al., 2011) or
result in a blunted response (Marshall et al., 2007), depending on
the particular ligand combination employed. Consequently, our
results do not clarify whether the cumulative, sometimes opposing
and sometimes synergistic, downstream effects of multiple simul-
taneous TLR activations are responsible for the enhanced resting
state degradation of tryptophan along the kynurenine pathway
in IBS. Moreover, it is unclear at present which receptor has the
greatest biological inﬂuence on kynurenine metabolism in vivo.
Nevertheless whole blood stimulation of single receptor subtypes
is considered a valid strategy to interrogate their responsiveness
in general and to determine whether particular patient popula-
tions are primed for aberrant responses (Pace and Heim, 2011).
Moreover, an assessment of the kynurenine:tryptophan ratio is a
previously validated method for the assessment of IDO activity in
cell culture supernatants (Schroecksnadel et al., 2005;Mahanonda
et al., 2007; Schroecksnadel et al., 2011). The fact that IBS popu-
lations show both basal alterations in this pathway and a distinct
proﬁle subsequent to stimulation of individual TLRs with their
various ligands only adds to their potential utility as biomark-
ers of the disorder, albeit as components of a biomarker panel of
other promising indices rather than as unique identiﬁers them-
selves. Further studies are urgently required, both to deﬁne such
a biomarker panel and to determine the sensitivity and speciﬁcity
of such an approach.
In conclusion, we have provided novel evidence demonstrating
that TLR activation induces a pattern of downstream tryptophan
degradation along the kynurenine pathway that differentiates IBS
patients from healthy controls. This bolsters current and previous
ﬁndings that highlighted baseline disturbances in this pathway
and illuminates a mechanism through which TLR responses can
functionally impact on brain-gut axis signaling in this disorder.
Moreover, this implicates the modulation of TLRs as a novel
therapeutic strategy in this debilitating condition.
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